Laidlaw Initiates Coverage on Arcturus Therapeutics (ARCT)

Laidlaw assumed coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research report sent to investors on Tuesday morning, The Fly reports. The firm issued a buy rating on the biotechnology company’s stock.

ARCT has been the topic of a number of other reports. Zacks Investment Research upgraded Arcturus Therapeutics from a hold rating to a buy rating and set a $5.25 target price on the stock in a report on Thursday, January 3rd. ValuEngine cut Arcturus Therapeutics from a buy rating to a hold rating in a report on Friday, December 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Arcturus Therapeutics currently has an average rating of Buy and an average price target of $5.25.

Shares of NASDAQ ARCT opened at $5.05 on Tuesday. Arcturus Therapeutics has a 52-week low of $4.11 and a 52-week high of $10.00.

Several hedge funds and other institutional investors have recently modified their holdings of ARCT. JPMorgan Chase & Co. boosted its position in shares of Arcturus Therapeutics by 91.7% in the third quarter. JPMorgan Chase & Co. now owns 16,744 shares of the biotechnology company’s stock worth $148,000 after buying an additional 8,008 shares during the period. BlackRock Inc. acquired a new stake in shares of Arcturus Therapeutics in the second quarter worth $169,000. Worth Venture Partners LLC acquired a new stake in shares of Arcturus Therapeutics in the third quarter worth $290,000. Finally, ARK Investment Management LLC boosted its position in shares of Arcturus Therapeutics by 45.0% in the third quarter. ARK Investment Management LLC now owns 773,772 shares of the biotechnology company’s stock worth $6,840,000 after buying an additional 239,999 shares during the period. Institutional investors and hedge funds own 10.29% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.

Featured Article: Asset Allocation and Your Retirement

The Fly

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.